Lisata Therapeutics Net Income Over Time
| LSTA Stock | USD 4.57 0.02 0.44% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lisata Therapeutics Performance and Lisata Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. Expected growth trajectory for Lisata significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Lisata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Lisata Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lisata Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Lisata Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Lisata Therapeutics and related stocks such as MetaVia, NuCana PLC, and Enlivex Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MTVA | (320 K) | (320 K) | (320 K) | (320 K) | (320 K) | (9 M) | (14.6 M) | (33.4 M) | (15.5 M) | (21.3 M) | (29.7 M) | (15.3 M) | (14 M) | (12.5 M) | (27.6 M) | (24.8 M) | (26.1 M) |
| NCNA | (6.2 K) | (6.2 K) | (6.2 K) | (6.2 K) | (6.2 K) | (5.3 M) | (6 M) | (23.1 M) | (13.8 M) | (21.4 M) | (30.7 M) | (40.5 M) | (32 M) | (27.6 M) | (19 M) | (17.1 M) | (18 M) |
| ENLV | (229 K) | (229 K) | (229 K) | (1.1 M) | (7 M) | (15.4 M) | (16 M) | (5.9 M) | (4.9 M) | (9.4 M) | (11.8 M) | (14.5 M) | (31.1 M) | (29.1 M) | (15 M) | (13.5 M) | (14.2 M) |
| PASG | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (45.6 M) | (112.2 M) | (185.4 M) | (136.1 M) | (102.1 M) | (64.8 M) | (58.3 M) | (61.2 M) |
| XCUR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (16.9 M) | (11 M) | (22.4 M) | (26.3 M) | (24.7 M) | (64.1 M) | (2.6 M) | (16.9 M) | (9.7 M) | (8.7 M) | (9.2 M) |
| CASI | (20 K) | (4.6 M) | (14.5 M) | (5.7 M) | (26.2 M) | (7.2 M) | (9.5 M) | (10.8 M) | (27.5 M) | (45.4 M) | (48.3 M) | (36.7 M) | (41 M) | (26.9 M) | (39.3 M) | (35.3 M) | (33.6 M) |
| PTHS | (660.6 K) | (660.6 K) | (660.6 K) | (660.6 K) | (660.6 K) | (660.6 K) | (660.6 K) | (660.6 K) | (660.6 K) | (660.6 K) | (660.6 K) | (595.4 K) | (2.5 M) | (7.4 M) | (8 M) | (7.2 M) | (6.8 M) |
| KLTO | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (913) | (1.1 M) | (598.6 K) | (707.5 K) | (6.2 M) | (5.5 M) | (5.3 M) |
| CLGN | (4.5 M) | (4.5 M) | (4.5 M) | (4.6 M) | (3.6 M) | (4.8 M) | (7.3 M) | (5.8 M) | (6.2 M) | (11.2 M) | (5.8 M) | 237 K | (16.9 M) | (7 M) | (16.6 M) | (14.9 M) | (14.2 M) |
Lisata Therapeutics and related stocks such as MetaVia, NuCana PLC, and Enlivex Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Lisata Therapeutics financial statement analysis. It represents the amount of money remaining after all of Lisata Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Lisata Therapeutics | LSTA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 110 Allen Road, |
| Exchange | NASDAQ Exchange |
USD 4.57
Check out Lisata Therapeutics Performance and Lisata Therapeutics Correlation. For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Lisata Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.